Liposomal chemotherapy CPX-351: safety profile
Revisiting clinical trial design – more adaptability in Phase I – III?
Elihu H. Estey
Cytokine release syndrome in CAR T-cell therapy
Safety profile of anti-CD19 CAR T-cell therapy axicabtagene ciloleucel
Encouraging data from the RAY trial 3-year follow-up